Epidemiology and differential diagnosis of NSAID-induced injury to the mucosa of the small intestine

Best Practice and Research: Clinical Gastroenterology

Volumn 15, Issue 5, 2001, Pages 723-738

  Smale, Simon ^a   Tibble, Jeremy ^a   Sigthorsson, Gudmundur ^a   Bjarnason, Ingvar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Drug toxicity; Enteropathy; Inflammatory bowel disease; Intestinal inflammation; Intestinal permeability; Non steroidal anti inflammatory drugs; Spondylarthropathy

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOTOXIC AGENT; DICLOFENAC; ETODOLAC; FENBUFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; METRONIDAZOLE; MISOPROSTOL; NABUMETONE; NAPROXEN; NEOMYCIN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROTEIN; PROTON PUMP INHIBITOR; ROFECOXIB; SALAZOSULFAPYRIDINE; SULINDAC;

ALGORITHM; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; ENTERITIS; GASTROINTESTINAL HEMORRHAGE; HUMAN; ILEITIS; ILEUM DYSFUNCTION; INTESTINE ENDOSCOPY; INTESTINE INJURY; LONG TERM CARE; PATHOGENESIS; PROTEIN DEPLETION; SMALL INTESTINE MUCOSA; SPONDYLOARTHROPATHY;

EID: 0034764858     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2001.0231     Document Type: Article

References (86)

1. Intestinal permeability and inflammation in rheumatoid arthritis: Effects of non-steroidal anti-inflammatory drugs
2. Nonsteroidal antiinflammatory drug induced intestinal inflammation in humans
3. Intestinal permeability and inflammation in patients on NSAIDs
4. Faecal calprotectin: A simple method for the diagnosis of NSAID-induced enteropathy
5. Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal antiinflammatory drugs
6. Small bowel enteroscopy in undiagnosed gastrointestinal blood loss
7. Use of anti-inflammatory drugs by patients with small or large bowel perforation and haemorrhage
8. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs
9. Aspirin: Intestinal damage in rats
10. Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-6-naphthylacetic acid (6MNA)
11. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ free rats
12. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs
13. Towards a better aspirin
14. NSAIDs, Cox-2 inhibitors, and the gut
15. Overview- mechanisms of action of anti-inflammatory drugs
16. The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis
17. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: The second hundred years
18. Profile and mechanisms of gastrointestinal and other side effects of nonsteroidal anti-inflammatory drugs (NSAIDs)
19. Towards a G1 safer antiinflammatory therapy
20. Effects of anionic surfactants on hamster small intestinal membrane structure and function: Relationship to surface activity
21. Laxative-like effects of nonsteroidal anti-inflammatory drugs on intestinal fluid movement and membrane integrity
22. ASA forms an ionic complex with phosphatidylcholine: Possible molecular explanation for its ulcerogenic action
23. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury
24. The relative importance of inhibition of cyclooxygenase and uncoupling of oxidative phosphorylation in the gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
25. Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation
26. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity
27. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine
28. Parietal cells of the stomach trap salicylates during absorption
29. Recent insight into the mechanism of gastrointestinal tract ulceration
30. Effect of prostaglandin acid on gastric mucosa II. Mucosal ATP and phosphocreatinine content and salicylic effects on mitochondrial metabolism
31. Mechanism of nonsteroidal anti-inflammatory drug-induced damage in the small bowel
32. Mitochondrial damage: A possible mechanism of the 'topical' phase of NSAID-induced injury to the rat intestine
33. Anti-inflammatory drug induced small intestinal permeability: The rat is a suitable model
34. Effect of the enantiomers of flurbiprofen, ibuprofen, and ketoprofen on intestinal permeability
35. Enantiomers of flurbiprofen can distinguish key pathophysiological steps of NSAID-enteropathy in the rat by steroselective inhibition of cyclooxygenase
36. Gastric ulceration induced by nonsteroidal antiinflammatory drugs is a neutrophil dependent process
37. A monoclonal antibody against the CD 18 leucocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit
38. Pathogenesis of NSAID gastropathy: Are neutrophils the culprits?
39. Pre-ulcerative villous contraction and microvascular occlusion induced by indomethacin in the rat jejunum
40. Vascular anatomy defines sites of indomethacin induced jejunal ulceration along the mesenteric margin
41. Early indomethacin lesions in rat jejunum: Reduced focal blood flow and shortening of villi precede ulceration
42. Reversal and protection against indomethacin-induced blood stasis and mucosal damage in the rat jejunum by a β-3-adrenoceptor agonist
43. Sublinical intestinal inflammation: An inherited abnormality in Crohn's disease relatives
44. Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel
45. Metronidazole reduces inflammation and blood loss in NSAID enteropathy
46. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss: Effect of sulphasalazine and other disease modifying drugs
47. Epidemiological evidence on the association between peptic ulceration and antiinflammatory drugs
48. Ulcers and strictures of the jejunum in a patient on long term indomethacin therapy
49. Ileal stricturing after long term indomethacin treatment
50. Small bowel ulceration in patients receiving NSAIDs for rheumatoid arthritis
51. Non-steroidal anti-inflammatory drug-induced enteritis
52. Diaphragm disease: The pathology of non-steroidal anti-inflammatory drug induced small intestinal strictures
53. 'Diaphragm like' strictures of the small bowel in patients treated with non-steroidal anti-inflammatory drugs
54. Clinico-pathological features of nonsteroidal antiinflammatory drug induced small intestinal strictures
55. 'Diaphragmlike' stricture and ulcer of the colon during diclofenac treatment
56. Diaphragm disease of the ascending colon associated with sustained release diclofenac
57. Nonsteroidal antiinflammatory drug-induced colonic strictures: A case report
58. Colonic strictures in a patient on long-term non-steroidal antiinflammatory drugs
59. Small bowel diaphragm disease - Strictures associated with non-steroidal anti-inflammatory drugs
60. Misoprostol in the treatment of NSAID-induced enteropathy: A double blind, placebo-controlled, parallel study
61. NSAID-injury to the small and large intestines
62. A randomised, double blind, double dummy, crossover study of the effects of nimesulide and naproxen on the gastrointestinal tract and an in vivo assessment of their selectivity for cyclooxygenase 1 and 2
63. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: A double blind crossover study comparing rofecoxib with placebo and indomethacin
64. Antiquity
65. The primary cause of rheumatoid arthritis is an infection. The infectious agent exists in milk
66. Historical aspects of the etiology of rheumatoid arthritis
67. Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history
68. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
69. The spondylitis of inflammatory bowel disease
70. Genetics of inflammatory bowel disease
71. HLA B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA B27 related arthritis
72. Ileocolonoscopic findings in seronegative spondyloarthropathies
73. Subclinical involvement of the gut in undifferentiated spondylarthropathies
74. Ileocolonoscopy in seronegative spondylarthropathy
75. Systematic ileocolonoscopy and bowel biopsy study in spondylarthropathy
76. High frequency of silent inflammatory bowel disease in spondylarthropathy
77. Intestinal histological and ultrastructural inflammatory changes in spondylarthropathy and rheumatoid arthritis
78. Ileocolonoscopic and histologic studies of Korean patients with anklylosing spondylitis
79. Macroscopic and microscopic gut lesions in seronegative spondylarthropathies
80. The histopathology of intestinal inflammation in reactive arthritis
81. A prospective study of patients with spondylarthropathy with special reference to HLA-B27 and gut histology
82. Gut and spondyloarthropathies
83. The evolution of spondylarthropathies in relation to gut histology. II. Histological aspects
84. Jejunal lesions in ankylosing spondilitis are due to nonsteroidal anti-inflammatory drug therapy
85. History of the development of sulphasalazine in rheumatology
86. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis